Pharma Focus Asia

Singapore-born digital therapeutics company inks deal with Hong Kong govt to fight COVID-19

Wednesday, March 04, 2020

As the novel coronavirus (COVID-19) continues to spread, a Singapore born, Boston-based digital therapeutics company has inked a deal with The University of Hong Kong and Hong Kong's Department of Health to leverage its cutting-edge wearable technology and AI-powered remote monitoring platform to provide new insights to fight COVID-19 in a national disease monitoring program. This first-of-its-kind program-which has international implications and applications-points to the value of the emerging category of digital therapeutics in monitoring patients with diagnosed or suspected COVID-19, while also helping clinicians better understand the disease so that they can better treat it.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024